OBJECTIVE: To explore the efficacies and adverse events of sorafenib in the treatment of advanced metastatic renal cell carcinoma.
METHODS: A total of 57 patients with advanced kidney cancer were recruited from our hospital from April 2007 to October 2011. They were divided into sorafenib group (A, n = 24) and sorafenib + IFN group (B, n = 33). The primary endpoints included objective response rate and progression-free survival (PFS). And the secondary endpoints were overall survival (OS) and incidence of adverse events.
RESULTS: The mean medication time of group A was 15 (7-56) months. The outcomes were partial response (PR, n = 1), stable disease (SD, n = 8), progressive disease (PD, n = 1) and death (n = 14). The rates of objective response and disease control were 4.2% (1/24) and 37.5% (9/24) respectively. For group B, the mean medication time was 15 (4-30) months. The outcomes were PR (n = 2), and include 2 patients of PR, 21 examples of SD, 1 patient of PD and death. The rates of objective response and disease control were 6.1% (2/33) and 69.7% (23/33) respectively. Two groups had no significant difference in incidence or severity of adverse events (both P > 0.05).
CONCLUSIONS: As a safe and effective agent for advanced kidney cancer, sorafenib is well-tolerated in patients. The combined use of interferon may improve the therapeutic efficacies without an occurrence of adverse events.
Written by:
Huang T, Song XS, Zhang ZW. Are you the author?
Department of Urology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Reference: Zhonghua Yi Xue Za Zhi. 2013 Jun 25;93(24):1903-5.
PubMed Abstract
PMID: 24124745
Article in Chinese.
UroToday.com Renal Cancer Section
